Figure S1, FGFR2 copy gain and overexpression in H716 cells A

Slides:

Advertisements

Similar presentations

NPV-BEZ235PKI-587 GDC-0980PD Supplemental Figure S1 Structures of Inhibitors NVP-BEZ235; PKI-587; GDC-0980 and PD

Advertisements

Suppl. Figure 1 A B Suppl. Figure 1. Relative (A) miR-21 and (B) miR-224 expression levels in HCC tumors in different stages (I,II,III,IV) assessed by.

Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post.

The c-Met receptor contributes to motility and invasion in high grade STS; a potential therapeutic target Sarah E. Myers, Theresa G. Nguyen, Quan-Sheng.

Kyoto University, Japan

HIGH-THROUGHPUT MUTATION PROFILING OF OSTEOSARCOMA PRIMARY TUMORS AND CELL LINES IDENTIFIES NEW MUTATIONS IN PREVIOUSLY UNASSOCIATED ONCOGENES AND TUMOR.

Fig. S1 1 Oxygen consumption rate (pmol/sec/10⁶cells) shLKB1#1 control * untreated 25 μM erlotinib H358 Vector LKB1 Oxygen consumption rate (pmol/sec/10⁶cells)

Cell lineStatus FGFR1 DMS-114Gene amplification NCI-H520Gene amplification NCI-H1581Gene amplification FGFR2 NCI-H716Gene amplification KATO-IIIGene amplification.

Chromosome Tumor samplesNormal samples Supplemental Figure 1.

Supplementary Figure S1 Inhibition of AKT and S6 phosphorylation. After 4 h treatment with 1 µM of GDC-0941, EVSA-T parental, resistant Clone1, Clone2,

The expression and signaling of FGFR3 in WM cells.

Overall (regardless of smoking Hx) Prior or current smoking Hx

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Article title: PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells Journal: Breast Cancer Research and.

From: Overexpression of the μ-Opioid Receptor in Human Non-Small Cell Lung Cancer Promotes Akt and mTOR Activation, Tumor Growth, and Metastasis Anesthes.

Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.

Supplementary Figure 1 Lapatinib nM mM pEGFR MDA-MB231 EGFR pEGFR

Figure 1. Herbacetin binds to AKT1/2 and suppresses each respective kinase activity. The effect of herbacetin on (A) PI3K/AKT and (B) MAPK signaling pathway.

Inhibition of FGFR fusion kinase activity repressed tumor growth in a mouse xenograft model. Inhibition of FGFR fusion kinase activity repressed tumor.

CDK2 is highly expressed in colon cancer cells and curcumin selectively suppresses HCT116 cell proliferation. CDK2 is highly expressed in colon cancer.

Volume 26, Issue 2, Pages (August 2014)

Phosphoinositide 3-kinase inhibitors protect mouse kidney cells from cyclosporine- induced cell death E. Sarró, O. Tornavaca, M. Plana, A. Meseguer, E.

Volume 71, Issue 6, Pages (June 2017)

Figure 1 A schematic representation of the HER2 signalling pathway

Volume 20, Issue 2, Pages (August 2011)

Bryan A. Whitson, MD, Blake A

Volume 29, Issue 3, Pages (March 2016)

Volume 131, Issue 5, Pages (November 2006)

黃其晟1 塗昭江1 張景年1 黃清水2 1天主教輔仁大學附設醫院乳房外科 2國泰綜合醫院外科部

Volume 19, Issue 1, Pages (January 2011)

Supplementary Figure S1: FGFR4 silencing synergistically enhances the effects of chemotherapy in colon cancer cells. siFGFR4 FGFR4_6 FGFR4_2 Neg Con FGFR4.

Volume 131, Issue 5, Pages (November 2006)

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Kavitha Gowrishankar, Stephanie Snoyman, Gulietta M. Pupo, Therese M

Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics Maksym.

An Autocrine Loop Mediates Expression of Vascular Endothelial Growth Factor in Human Dermal Microvascular Endothelial Cells Barbara Vega-Diaz, Serge.

Synchronized Targeting of Notch and ERBB Signaling Suppresses Melanoma Tumor Growth through Inhibition of Notch1 and ERBB3 Keman Zhang, Poki Wong, Christine.

Olga C. J. Schuurbiers, MD, Johannes H. A. M

The Genetic Landscape of Malignant Pleural Mesothelioma: Results from Massively Parallel Sequencing Marieke Hylebos, MSc, Guy Van Camp, PhD, Jan P van.

Fig. 6. FGFR1 and CCND1 amplification–mediated resistance to estrogen deprivation is therapeutically actionable. FGFR1 and CCND1 amplification–mediated.

Volume 11, Issue 3, Pages (April 2015)

Volume 6, Issue 2, Pages (August 2004)

(apoptotic + necrotic)

Supplementary Figure 1 A B C CD56 D E F CD56.

Volume 26, Issue 2, Pages (August 2014)

Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy Marie Brevet, MD, PhD, Shigeki Shimizu,

Growth hormone reduces chloride secretion in human colonic epithelial cells via EGF receptor and extracellular regulated kinase1 Jimmy Y.C Chow, Katie.

FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy Alvaro Quintanal-Villalonga, PhD, Sonia.

p38 MAPK activation is required for phosphorylation of Akt at Ser473.

Kimita Suyama, Irina Shapiro, Mitchell Guttman, Rachel B. Hazan

Figure S2 ARK5/NUAK1 Aurora A PKN1/PRK1 CK1g2 PAK5 HPK1/MAP4K1 ABL1

A 4h of treatment 72h of treatment 1mM PI3Kbi

Volume 11, Issue 3, Pages (April 2015)

CEP55 is a downstream effector of MAPK signaling

Daniel B. Costa, MD, PhD, Susan E. Jorge, PhD, Jason P

Molecular Therapy - Nucleic Acids

P38 activation mediates chronic insulin-induced IRS1 and IRS2 degradation and is involved in myocardial insulin resistance in vitro. p38 activation mediates.

eNOS regulated IR-induced NO generation and EGFR signal activation.

Figure 5. Effect of insulin-like growth factor 1 (IGF-1) induced extracellular regulated protein kinases 1/2 (ERK1/2) activation and the signal-responsive.

a b 10A.zp85WT 10A.zp85S83μ 10A.vec 10A.z 10A.vec 10Az 10Az.p85WT

AG1024 reduced the level of tyrosyl-phosphorylated proteins, including Erk2. AG1024 reduced the level of tyrosyl-phosphorylated proteins, including Erk2.

Sensor siRNAs can be used in high-order combinations.

Down-regulation of the erbB-2 receptor by trastuzumab decreases Akt kinase activation but not MAPK activation. Down-regulation of the erbB-2 receptor by.

Sample-wise outlier kinases in ERBB2-positive breast cancer cell lines

Expression of CRC stem cell markers and L1 in CRC cells.

Expression of versican promoted breast cancer cell self-renewal through enhanced EGFR/AKT/GSK-3β (S9P) signals. Expression of versican promoted breast.

FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung cancer cell lines. FGFR1 is dominantly expressed in mesenchymal-like KRAS-mutant lung.

BCR/ABL expression, tyrosine phosphorylation, and signaling in dasatinib- and imatinib-resistant cell lines and the ubiquitin inhibitor lactacystin modifies.

FGF19 amplification in liver cancer cell lines is associated with response to NVP-BGJ398. FGF19 amplification in liver cancer cell lines is associated.

AXL is not necessary for maintenance of intrinsic resistance.

Presentation transcript:

Figure S1, FGFR2 copy gain and overexpression in H716 cells A View Key NCI H716 colon adenocarcinoma B FGFR2 (MB 122) KATOIII gastric cancer FGFR2 (MB 122)

Figure S1C: Selective FGFR2 overexpression in H716, KATOIII and SNU16 cell lines in Wooster Cell Line C Reporter: 10-123287897 10-123287897 KatoIII SNU16 H716 18,823 measured genes 338 samples

Figure S2: FGF2 does not further activate FGFR2 in H716 or colon cancer cell lines. p-FGFR2 Actin H716 H508 LS411N H747 RKO SW48 SW620 SW480 DLD1 + - + - + - + - + - + - + - + - + - -150 - 40 FGF2 FGFR2

Figure S3: AMBIT panel with 100nM PD173074 80-100%activity : Kinase % Control FGFR1 1.4 FGFR3 1.6 FGFR2 2.4 DDR1 18 MKNK1 34 FLT4 35 PIK3CB CSF1R 36 NEK4 54 NEK11 55 FGFR4 56 STK25 57 STK24 58 CHUK 62 NUAK1 67 MAPK13 MAP2K4 68 NTRK2 MATK 69 ERBB3 ABL1 70 RIOK2 71 AKT1 72 BTK DCLK1 CDK4 73 PIK3CA HIPK2 74 EGFR 76 MAP2K6 RPS6KA4 NUAK2 FLT3 77 HUNK MAPK9 STK3 KDR DYRK2 78 LCK MAP3K3 TAOK3 TRPM6 CDKL3 79 EIF2AK2 TSSK1B MAP3K2 80 PDGFRB PLK1

Figure S4: PD173074 Inhibits pFGFR2 and selectively inhibits NCI-H716 growth 20 40 60 80 100 Untreated Gleevec Tarceva Lapatinib PD173074 anti IGF1R PHA665752 PD168393 T = 0 T = 3 days B A IC50

Figure S5: pRSK S359/363 (ERK phosphorylation site) is inhibited by PD173074 -100 -75 PD173074 : - + GAPDH

Figure S6: L-547 and Rapamycin inhibit Akt and S6RP phosphorylation pAkt -60 1uM L547 : - + GAPDH Akt pS6RP S6RP -35 Rapamycin - + A B

. Figure S7: PD173074 causes cell death in NCI-H716 cells PD173074 100nM Figure S7: PD173074 causes cell death in NCI-H716 cells . Untreated

Figure S8: E cadherin and EPCAM are not expressed in H716 cells Actin H716 H508 LS411N H747 RKO SW48 SW620 SW480 DLD1 + - + - + - + - + - + - + - + - + - -- 120 -150 -40 FGF2 CDH1 EPCAM -30